Autolus Therapeutics PLC (NASDAQ: AUTL) has disclosed its plan to collaborate with Moderna Inc (NASDAQ: MRNA) in a deal that will see the two focus on the development of mRNA therapeutics. The focus happens to be on about four immuno-oncology targets, and they will incorporate Autolus’ proprietary binders in the development undertaking.
The upfront payment
The terms of the deal entitle Autolus to an upfront payment, which will be for each of the targets that Moderna licenses. It will also be entitled to the commercial and development milestone payments that will emanate from every product successfully commercialized.
Reports also show that Autolus will be getting royalties on net sales as an entitlement from all the products that will commercialize under the deal in question.
Pulé and his perspective
The founder and chief scientific officer of Autolus, Dr. Martin Pulé, applauds Moderna for settling on Autolus as a partner. He expects a lot from this collaboration focused on some particular mRNA-based therapeutics in oncology indications.
Pulé opines, “The use of our technology in Moderna’s mRNA platform underscores Autolus’ leadership in the development of innovative differentiated binder and cell programming technologies.”
Autolus Therapeutics continues making plans to become more successful in developing its programmed T cell therapies and considers the latest deal to be a step towards advancing its goals and aspirations. Moderna is, on the other hand, known for its RNA (mRNA) therapeutics and vaccines.
It is a new dawn for the company as it gets an exclusive license that will give it the freedom to develop mRNA therapeutics through incorporating Autolus’ proprietary binders. It understands all the four immuno-oncology targets and seeks to do its best to achieve the most outstanding results.
Solid tumors and hematological malignancies have been causing many deaths globally, but Autolus seeks to change that using its pipeline of product candidates under development.